





RealRate

# PHARMACEUTICAL 2022

Kiniksa Pharmaceuticals Ltd.  
Rank 244 of 466



The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Expenses, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 114%, being 36% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	196,446
Cost of Goods Sold	9,100
Intangible Assets	19,250
Liabilities, Current	44,824
Liabilities, Non-Current	2,939
Other Assets	14,270
Other Compr. Net Income	-32
Other Expenses	2,220
Other Liabilities	0
Other Net Income	97
Other Revenues	38,544
Property and Equipment	2,834
Research and Development	99,297
Selling, General and Administrative Expense	85,948

Output Variable	Value in 1000 USD
Assets	232,800
Liabilities	47,763
Expenses	196,565
Revenues	38,544
Stockholders Equity	185,037
Net Income	-157,924
Comprehensive Net Income	-157,940
Economic Capital Ratio	114%